March 01, 2015 8:44 PM ET

Life Sciences Tools and Services

Company Overview of Antitope Ltd

Company Overview

Antitope Ltd., a biotechnology research company, develops non-immunogenic protein therapeutics. The company specializes in immunogenicity testing and the engineering of therapeutic antibodies/proteins with reduced immunogenicity. It offers EpiScreen, an ex vivo human T cell assay technology for predicting the immunogenicity of biologics or for identifying T cell epitopes within the sequences of biologics; Composite Human Antibody technology for generating humanized antibodies devoid of human T cell epitopes; and Composite Protein technology for generating therapeutic proteins devoid of human T cell epitopes. The company also provides pANT Vector System, an expression system to enhance expres...

Babraham Research Campus

Babraham

Cambridge,  CB22 3AT

United Kingdom

Founded in 2004

Phone:

44 1223 496190

Fax:

44 1223 496191

Key Executives for Antitope Ltd

Chief Executive Officer and Director
Age: 46
Co-Founder, Chief Scientific Officer and Director
Age: 43
Chief Financial Officer
Age: 49
Vice President of Business Development
Research Director
Compensation as of Fiscal Year 2014.

Antitope Ltd Key Developments

Antitope, INSERM and Baylor Institute to Collaborate to Produce Manufacturing Cell Lines for Two Novel Vaccines for HIV

Antitope Limited announced that it has extended its relationship with INSERM, ANRS and the Baylor Institute for Immunology Research. INSERM-ANRS and the BIIR have developed innovative approaches for HIV vaccines targeting HIV antigens to dendritic cells (DC) using monoclonal antibodies fused to HIV antigens. Extensive preclinical data has demonstrated the high immunogenicity of the candidate vaccines. Antitope will produce cell lines for GMP manufacture of two anti-CD40-HIV fusion proteins that INSERM-ANRS and BIIR are developing as potential therapeutic and prophylactic vaccines to treat HIV. The cell lines will be produced using Antitope’s Composite CHO™ technology. The antibody component of the fusion proteins has previously been humanized by Antitope using its Composite Human Antibody™ technology. Phase I and Phase II clinical trials will be conducted in France to test the immunogenicity and efficacy of these DC-targeting vaccines developed by INSERM-ANRS in partnership with the BIIR.

Antitope Limited and University College London Enter into Research & Licence Agreement for Generation of Fully Humanized Antibodies

Abzena plc announced that its wholly-owned subsidiary Antitope Limited and University College London (UCL) will collaborate to humanize an anti-LRG1 antibody as part of a MRC-funded translational research and product development programme being undertaken by the UCL Institute of Ophthalmology. The collaboration is supported by UCL Business PLC (UCLB), UCL's wholly owned technology transfer company, which provided initial Proof of Concept funding and holds the patents to the LRG1 technologies. LRG1 (leucine-rich alpha-2-glycoprotein 1) was identified by researchers at UCL to promote the growth of blood vessels (a process known as angiogenesis). Antitope will produce a range of fully humanized antibodies using its Composite Human Antibody technology that are designed to bind to and inhibit the function of LRG1. UCL will select a lead antibody for further evaluation as a potential therapeutic product for the treatment of age-related macular degeneration (AMD). UCLB is continuing to support development of this technology and is currently seeking commercial partners to take it to market.

Similar Private Companies By Industry

Company Name Region
InoCardia Ltd Europe
BioFocus DPI Ltd Europe
Pathology Diagnostics Ltd. Europe
MW Encap Ltd. Europe
Equibio Limited Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Antitope Ltd, please visit www.antitope.co.uk. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.